Santos FC

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2020, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program Read More »